COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND. Proceedings of the International Conference on Public Health, [S. l.], v. 9, n. 1, p. 45–67, 2025. DOI: 10.17501/24246735.2024.9105. Disponível em: https://www.proceedings.tiikmpublishing.com/index.php/icoph/article/view/1543. Acesso em: 14 oct. 2025.